– Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Ferme C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G.

Long-term follow-up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma


– Narquin S, Ingrand P, Azais I, Delwail V, Vialle R, Boucecbi S, Tasu JP.

Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma.

Diagn Interv Imaging

– Clarhaut J, Fraineau S, Guilhot J, Peraudeau E, Tranoy-Opalinski I, Thomas M, Renoux B, Randriamalala E, Bois P, Chatelier A, Monvoisin A, Cronier L, Papot S, Guilhot F.

A galactosidase-responsive doxorubicin-folate conjugate for selective targeting of acute myelogenous leukemia blasts

Leukemia Research

– Puyade M, Yacoub M, Tomowiak C, Diviné M, Perdrisot R, Guilhot F, Delwail V.

Failure of fluorodeoxyglucose positron emission tomography to detect the high-grade transformation of nodular lymphocyte predominant Hodgkin’s lymphoma

Acta Haematol 129(4):229-31. doi: 10.1159/000345261. Epub 2013 Jan 11.

– Marina G. Yefimova,Nadia Messaddeq Thomas Harnois, Annie-Claire Meunier, Jonathan Clarhaut, Anaïs Noblanc,Jean-Luc Weickert, Anne Cantereau, Michel Philippe, Nicolas Bourmeyster, Omar Benzakour

A chimerical phagocytosis model reveals the recruitment by Sertoli cells of autophagy for the degradation of ingested illegitimate substrates

Autophagy 2013 May;9(5):653-66. doi: 10.4161/auto.23839. Epub 2013 Feb 25

– Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M.

Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase

Pediatr Blood Cancer 2013 Sep 17. doi: 10.1002/pbc.24521

– Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

N Engl J Med 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494

– Rousselot P, Cony-Makhoul P, Nicolini F, Mahon FX, Berthou C, Réa D, Reiffers J, Bornand A, Saint-Jean O, Guilhot J, Guilhot F; French Intergroup For Chronic Myelogenous Leukemia (Fi-LMC).

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.

AM J HEMATOLOL, 2013 Jan;88(1):1-4. doi: 10.1002/ajh.23330. Epub 2012 Sep 17.

Guilhot F, Coombs J, Szczudlo T, Zernovak O, Paolantonio M, Bender C, Macdonald NJ, Shapiro A

The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach.

Patient 2013;6(2):81-92. doi: 10.1007/s40271-013-0006-3

– Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

BLOOD 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.

– Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, Royer B, Dib M, Voillat L, Bouscary D, Caillot D, Wetterwald M, Pegourie B, Lepeu G, Corront B, Karlin L, Stoppa AM, Fuzibet JG, Delbrel X, Guilhot F, Kolb B, Decaux O, Lamy T, Garderet L, Allangba O, Lifermann F, Anglaret B, Moreau P, Harousseau JL, Facon T.

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

J Clin Oncol 2013 Aug 1;31(22):2806-9. doi: 10.1200/JCO.2012.46.2598. Epub 2013 Jun 24.

– Grinda M, Legigan T, Clarhaut J, Peraudeau E, Tranoy-Opalinski I, Renoux B, Thomas M, Guilhot F, Papot S.

An enzyme-responsive system programmed for the double release of bioactive molecules through an intracellular chemical amplification process

The Royal Society of Chemistry 2013 2013 Nov 7;11(41):7129-33. doi: 10.1039/c3ob41536h

– Johnson-Ansah H, Guilhot J, Rousselot P, Rea D, Legros L, Rigal-Huguet F, Nicolini FE, Mahon FX, Preudhomme C, Guilhot F.

Tolerability and efficacy of pegylated interferon-a-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.

Cancer. 2013 Dec 15;119(24):4284-9. doi: 10.1002/cncr.28328. Epub 2013 Sep 16.

– Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F.

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

Qual Life Res. 2013 Sep 13. [Epub ahead of print]

– Rodrigues CA, Rocha V, Dreger P, Brunstein CG, Sengeloev H, Finke J, Mohty M, Rio B, Petersen E, Guilhot F, Niederwieser D, Cornelissen JJ, Jindra P, Nagler A, Fegueux N, Schoemans H, Robinson S, Ruggeri A, Gluckman E, Canals C, Sureda A.

Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood.

Haematologica. 2013 Aug 9. [Epub ahead of print]

– Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechignac S, Pegourie B, Jaubert J, Dib M, Stoppa AM, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H.

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

Leukemia. 2013 Jul 29. doi: 10.1038/leu.2013.225. [Epub ahead of print]

– Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

J Clin Oncol 2013 Dec 9. [Epub ahead of print]

– Tea I, Le Guennec A, Frasquet-Darrieux M, Julien M, Romek K, Antheaume I, Hankard R, Robins RJ.

Simultaneous determination of natural-abundance d(15) N values and quantities of individual amino acids in proteins from milk of lactating women and from infant hair using gas chromatography/isotope ratio mass spectrometry.

Rapid Commun Mass Spectrom

– de Luca A, Parizel A, Fromont G, Roblot P, Roblot F, Gambert-Abdel Rahman C, Hankard R

High procalcitonin and thrombocytopenic purpura in a case of Kikuchi-Fujimoto disease.

Arch Pediatr 2013 Jun 11. pii: S0929-693X(13)00294-7. doi: 10.1016/j.arcped.2013.04.016.

– Mohammedi K, Patente TA, Bellili-Muñoz N, Driss F, Monteiro MB, Roussel R, Pavin EJ, Seta N, Fumeron F, Azevedo MJ, Canani LH, Hadjadj S, Marre M, Corrêa-Giannella ML, Velho G

Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes.

Diabetologia 2013 Dec;56(12):2733-42. doi: 10.1007/s00125-013-3057-z.

– Bonnefond A, Saulnier PJ, Stathopoulou MG, Grarup N, Ndiaye NC, Roussel R, Nezhad MA, Dechaume A, Lantieri O, Hercberg S, Lauritzen T, Balkau B, El-Sayed Moustafa JS, Hansen T, Pedersen O, Froguel P, Charpentier G, Marre M, Hadjadj S, Visvikis-Siest S.

What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications?

PLOS ONE 2013;8(2):e55921. doi: 10.1371/journal.pone.0055921

– Roussel R, Hadjadj S, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Tubach F, Marre M, Porath A, Krempf M, Bhatt DL, Steg PG.

Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.

Int J Cardiol 2013 Aug 20;167(4):1380-4. doi: 10.1016/j.ijcard.2012.04.019.

– Burbaud P, Clair AH, Langbour N, Fernandez-Vidal S, Goillandeau M, Michelet T, Bardinet E, Chéreau I, Durif F, Polosan M, Chabardès S, Fontaine D, Magnié-Mauro MN, Houeto JL, Bataille B, Millet B, Vérin M, Baup N, Krebs MO, Cornu P, Pelissolo A, Arbus C, Simonetta-Moreau M, Yelnik J, Welter ML, Mallet L; French Stimulation dans le Trouble Obsessionnel Compulsif Study Group.

Neuronal activity correlated with checking behaviour in the subthalamic nucleus of patients with obsessive-compulsive disorder


– Rotge JY, Langbour N, Dilharreguy B, Bordessoulles M, Guehl D, Bioulac B, Martin-Guehl C, Jaafari N, Aouizerate B, Allard M, Burbaud P.

Contextual and behavioral influences on uncertainty in obsessive-compulsive disorder.


– Millet B, Dondaine T, Reymann JM, Bourguignon A, Naudet F, Jaafari N, Drapier D, Turmel V, Mesbah H, Vérin M, Le Jeune F.

Obsessive compulsive disorder networks: positron emission tomography and neuropsychology provide new insights.

PLoS One. 2013;8(1):e53241. doi: 10.1371/journal.pone.0053241. Epub 2013 Jan 11.

– Tordjman S, Najjar I, Bellissant E, Anderson GM, Barburoth M, Cohen D, Jaafari N, Schischmanoff O, Fagard R, Lagdas E, Kermarrec S, Ribardiere S, Botbol M, Fougerou C, Bronsard G, Vernay-Leconte J.

Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives

Int J Mol Sci 2013 Oct 14;14(10):20508-42. doi: 10.3390/ijms141020508

– Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R.

Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria.

Diabetes Care

Fritel X, Lachal L, Cassou B, Fauconnier A, Dargent-Molina P.

Mobility impairment is associated with urge but not stress urinary incontinence in community-dwelling older women: results from the Ossébo study.

BJOG 2013 Jun 10. doi: 10.1111/1471-0528.12316.

– Javaugue V, Karras A, Glowacki F, McGregor B, Lacombe C, Goujon JM, Ragot S, Aucouturier P, Touchard G, Bridoux F.

Long-term Kidney Disease Outcomes in Fibrillary Glomerulonephritis: A Case Series of 27 Patients

Am J Kidney Dis 2013 Jun 4. pii: S0272-6386(13)00714-2. doi: 10.1053/j.ajkd.2013.03.031.

– Gavazzi G, Delerce E, Cambau E, François P, Corroyer B, de Wazières B, Fougère B, Paccalin M, Gaillat J.

Diagnostic criteria for urinary tract infection in hospitalized elderly patients over 75 years of age: A multicenter cross-sectional study.

Médecine et maladies infectieuses

– Marret H, Fernandez H, Fritel X, Herbreteau D.

Myoma management: New guidelines

La presse médicale

– Jouhet V, Defossez G; CRISAP; CoRIM, Ingrand P.

Automated Selection of Relevant Information for Notification of Incident Cancer Cases within a Multisource Cancer Registry.

Methods Inf Med

– Lucot JP, Fritel X, Debodinance P, Bader G, Cosson M, Giraudet G, Collinet P, Rubod C, Fernandez H, Fournet S, Lesavre M, Deffieux X, Faivre E, Trichot C, Demoulin G, Jacquetin B, Savary D, Botchorichvili R, Campagne Loiseau S, Salet-Lizee D, Villet R, Gadonneix P, Delporte P, Ferry P, Aucouturier JS, Thirouard Y, de Tayrac R, Fatton B, Wagner L, Nadeau C, Wattiez A, Garbin O, Youssef Azer Akladios C, Thoma V, Baulon Thaveau E, Saussine C, Hermieu JF, Delmas V, Blanc S, Tardif D, Fauconnier A; GROG (groupe de recherche en gynécologie et obstétrique).

PROSPERE randomized controlled trial: Laparoscopic sacropexy versus vaginal mesh for cystocele POP repair

journal gynecologie obstétrique

Efficacy and safety of pegylated-interferon a-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups

Br J Haematol 2013 Sep;162(6):783-91. doi: 10.1111/bjh.12459. Epub 2013 Jul 13.

– Ansquer S, Belin-Rauscent A, Dugast E, Duran T, Benatru I, Mar AC, Houeto JL, Belin D.

Atomoxetine Decreases Vulnerability to Develop Compulsivity in High Impulsive Rats.

Biol Psychiatry 2013 Oct 11. pii: S0006-3223(13)00904-9. doi: 10.1016/j.biopsych.2013.09.031. [Epub ahead of print]

– Mimoun C, Fritel X, Fauconnier A, Deffieux X, Dumont A, Huchon C.

Épidémiologie des tumeurs ovariennes présumées bénignes

– Desseauve D, Pierre F, Fritel X.

Urinary incontinence in women: study of surgical practice in France.

Prog Urol. 2013 Apr;23(4):249-55. doi: 10.1016/j.purol.2012.12.005

Fritel X, Khoshnood B, Fauconnier A.

Specific obstetrical risk factors for urinary versus anal incontinence 4years after first delivery.

Prog Urol. 2013 Sep;23(11):911-6. doi: 10.1016/j.purol.2013.06.009

– Testefort A, Giraudeau B, Lamireau T, Tounian P, Dubus JC, Chabrol B, Bader-Meunier B, Hankard R

Evaluation of the abstracts submitted to the French Society of Pediatrics (SFP) in 2012

Arch Pediatr 2013 Mar;20(3):315-6. doi: 10.1016/j.arcped.2012.12.022.

Hankard R, Tounian P, Chabrol B.

Research: a priority for the French Society of Pediatrics (SFP)

Arch Pediatr 2013 Mar;20(3):217-8. doi: 10.1016/j.arcped.2012.12.018.

– Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N.

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.

Bone Marrow Transplant 2013 Nov;48(11):1395-400. doi: 10.1038/bmt.2013.73. Epub 2013 May 27.

Fritel X, Dumoulin C.

Incontinence: Stress urinary incontinence treatment-surgery first?

Nat Rev Urol. 2013 Dec 10. doi: 10.1038/nrurol.2013.300.

Fritel X, Panjo H, Varnoux N, Ringa V.

The individual determinants of care-seeking among middle-aged women reporting urinary incontinence: Analysis of a 2273-woman cohort.

Neurourol Urodyn 2013 Jul 1. doi: 10.1002/nau.22461.

– Brun JL, Fritel X, Levêque J.

Clinical practice guidelines: Presumed benign ovarian tumors – Aims, methods, and organization.

J Gynecol Obstet Biol Reprod (Paris). 2013 Dec;42(8):710-4. doi: 10.1016/j.jgyn.2013.09.025.

– Billecocq S, Morel MP, Fritel X.

Levator ani trauma after childbirth, from stretch injury to avulsion: review of the literature.

Prog Urol 2013 Jun;23(8):511-8. doi: 10.1016/j.purol.2013.04.003.

– Pizzoferrato AC, Fauconnier A, Quiboeuf E, Morel K, Schaal JP, Fritel X.

Urinary incontinence 4 and 12 years after first delivery: Risk factors associated with prevalence, incidence, remission, and persistence in a cohort of 236 women.

Neurourol Urodyn 2013 Oct 16. doi: 10.1002/nau.22498.

Fritel X, Fauconnier A.

Does the SWEPOP (Swedish Pregnancy, Obesity and Pelvic Floor) study suffer from a selection bias?

BJOG. 2013 Nov;120(12):1578-9. doi: 10.1111/1471-0528.12417.


Menu principal

Haut de page